- Founded
- 2010
- Employees
- 175
- Total Funding
- $398M
Founded by Nevan Elam in 2010.
About Rezolute
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Our antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI) The Director Program Manager will be a key member of the Program Management Office (PMO), responsible for Launch execution plan for the company’s first rare disease drug launch. This individual will partner closely with key stakeholders and executives from Commercial, Medical Affairs, Regulatory...
Leadership at Rezolute
The team at the top of the org chart.
Nevan Charles Elam
CEO & Founder
50 reports
Brian Roberts
Chief Medical Officer
13 reports
Michael R. Deperro
Senior Vice President, Operations
16 reports
Jeffrey Breit, Ph.D.
Vice President, Drug Discovery and Pharmaceutical Sciences
1 report
Susan Stewart, JD, LL.M
Chief Regulatory Officer
2 reports
Melissa Q.
Vice President, People & Culture
Daron Evans
Chief Financial Officer
6 reports
Sunil Karnawat
Chief Commercial Officer (cco)
5 reports
Board
Young-Jin Kim
Chairman
Nerissa Kreher
Director
Vlad Hogenhuis
Director
Gil Labrucherie
Director
Philippe Fauchet
Director
Robert B. Bhisitkul
Scientific Advisor